Reviewer's report

**Title:** The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

**Version:** 1  **Date:** 4 September 2012

**Reviewer:** Dorothy M Keefe

**Reviewer's report:**

This is an interesting clinical study investigating changes in intestinal permeability and growth factor levels in breast cancer patients undergoing chemotherapy with a risk for chemotherapy-induced diarrhoea.

In general I think this is a useful study but there are a couple of minor issues. Firstly, although very well written there are a few occasions where the English is a little hard to understand, and it might benefit from review by a native English speaker.

Secondly the figures did not appear well on the website so I was unable to adequately review them.

Thirdly the discussion is a little bit long and could be tightened.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I have done consulting work with a company that makes a Glp-2 analogue, and with companies that do research into the causes and treatment of GI mucositis.